What You Should Know:
– ForSight Robotics, the pioneer in ophthalmic robotic surgery secures $125M Series B round, led by Eclipse.
– The investment will accelerate the next growth phase for the ORYOM™ Platform, the world’s first robotic surgery platform for cataract and other eye diseases, as the company prepares to launch first-in-human clinical trials this year.
– The funding round, which brings ForSight Robotics’ total funding to $195M, also included significant participation from an undisclosed strategic investor, as well as Dr. Fred Moll, the Adani Group, Reiya Ventures, and other existing investors.
Addressing a Global Vision Crisis
The investment comes at a critical time, as a global vision crisis, marked by over one billion people suffering from preventable vision impairment, intersects with a declining ophthalmologist workforce. By 2035, the industry expects a 12% decline in ophthalmologists, while demand for care is projected to increase by 24%.
Specifically for cataracts, over 600 million patients are affected globally, yet only 30 million receive surgical treatment each year. ForSight Robotics aims to address this disparity by enhancing surgical precision and increasing patient access to high-quality treatment.
“We see ophthalmology as the next frontier in the robotics revolution – much like general surgery was before the rise of Intuitive Surgical,” said Dr. Joseph Nathan, ForSight Robotics’ co-founder, president, and Chief Medical Officer. “With a comparable market size and an urgent global need, our opportunity ahead is immense.”
The ORYOM™ Platform
The ORYOM™ Platform is engineered for highly precise and consistent ophthalmic procedures, beginning with cataract surgery. The platform leverages:
- AI-based algorithms
- Advanced computer vision
- State-of-the-art micromechanics
This combination delivers unprecedented dexterity and maneuverability while providing surgeons with an improved ergonomic experience. The platform can reach any point within the human eye, allowing surgeons to navigate complex angles and access both anterior and posterior segments, setting the stage for future treatments in glaucoma and retinal surgery.
Recent Traction/Milestones
The Series B funding follows a period of rapid growth for ForSight Robotics. Over the past year, the company has doubled in size to over 110 employees, achieved ISO 13485:2016 certification, and successfully completed hundreds of procedures on animal eye models with the ORYOM™ Platform. The company is set to begin robotic cataract surgery clinical trials in the coming year.
